论文部分内容阅读
深入研究系统性红斑狼疮(SLE)的发病机制对于临床探索新的治疗方式和新药研发有重要意义,目前仍以糖皮质激素类和大剂量免疫抑制剂冲击治疗为主要治疗手段。然而,它们的严重副作用和并发症不容小觑,这使得人们开始寻找更加特异有效及较低毒副作用的治疗方法和药物。目前的研究热点是B淋巴细胞靶点与SLE发病机制之间的关系,现临床常用的特异性生物制剂主要靶向B细胞表面分子CD20、CD22、B细胞活化因子(BAFF)和调节性B细胞分泌的IL-10,本文主要综述了这几个靶点在SLE中的调节作用及其相关生物制剂的临床应用。
In-depth study of the pathogenesis of systemic lupus erythematosus (SLE) for clinical exploration of new treatment methods and new drug development is of great significance, is still still glucocorticoid and high-dose immunosuppressive therapy as the main treatment. However, their serious side effects and complications should not be underestimated, leading to the search for more specific and effective treatment methods and drugs with less toxic side effects. The current research focus is the relationship between the B lymphocyte target and the pathogenesis of SLE. Currently, the specific biological agents commonly used in clinic mainly target the B cell surface molecules CD20, CD22, B-cell activating factor (BAFF) and regulatory B cells Secretion of IL-10, this article mainly reviewed the regulation of these targets in SLE and its clinical application of biological agents.